Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Operating Margin (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Operating Margin for 14 consecutive years, with 52.36% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 5006.0% year-over-year to 52.36%, compared with a TTM value of 62.1% through Dec 2025, up 2014.0%, and an annual FY2025 reading of 62.1%, up 2014.0% over the prior year.
  • Operating Margin was 52.36% for Q4 2025 at Karyopharm Therapeutics, down from 34.56% in the prior quarter.
  • Across five years, Operating Margin topped out at 37.19% in Q4 2021 and bottomed at 225.16% in Q1 2021.
  • Average Operating Margin over 5 years is 92.27%, with a median of 86.07% recorded in 2022.
  • Peak annual rise in Operating Margin hit 15261bps in 2022, while the deepest fall reached -13805bps in 2022.
  • Year by year, Operating Margin stood at 37.19% in 2021, then crashed by -371bps to 100.86% in 2022, then dropped by -11bps to 112.03% in 2023, then increased by 9bps to 102.42% in 2024, then skyrocketed by 49bps to 52.36% in 2025.
  • Business Quant data shows Operating Margin for KPTI at 52.36% in Q4 2025, 34.56% in Q3 2025, and 64.3% in Q2 2025.